Geron Corporation Share Price & Technical Analysis
GERN · $1.29 (+0.78%)
Healthcare / Biotechnology
$1.29
+0.78%
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower…
Price chart
Seasonality
May has 2 positive and 2 negative years (last 5 years shown)
-13% return in May, 9% avg return in past 3 year May month.
10% return in 2026, -1% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 8% | 21% | -6% | 0% | -13% | – | – | – | – | – | – | – | 10% |
| 25 | -19% | -36% | -11% | -12% | 7% | -7% | -21% | 27% | 0% | -7% | -8% | 18% | -69% |
| 24 | -14% | 5% | 65% | 18% | -12% | 14% | 12% | 2% | -4% | -9% | 0% | -15% | 61% |
| 23 | 32% | -15% | -21% | 19% | 32% | -3% | 0% | -25% | -16% | -10% | 0% | 11% | 3% |
| 22 | -8% | 0% | 27% | 0% | 0% | 7% | 27% | 37% | -12% | -8% | 5% | 4% | 79% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$901.34M
P/E ratio
—
52W high
$2.01
52W low
$1.04
Volume
92,34,053
Beta
0.68
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Geron Corporation share price today?
- Geron Corporation (GERN) last traded around $1.29 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does GERN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for GERN. Download the app for real-time alerts.
- How can I analyze Geron Corporation stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.